🧪
hypothesis

Lipid Droplet Dynamics as Therapeutic Lever

Hypothesis

Lipid Droplet Dynamics as Therapeutic Lever

Target DGAT1/DGAT2 inhibition or ATGL activation to restore metabolic homeostasis by addressing lipid metabolism dysfunction unique to APOE4 carriers.
🧬 DGAT1🩺 neurodegeneration🎯 Composite 46%💱 $0.52▲5.7%active
EvidencePending (0%)📖 5 cit🗣 1 debates 5 support 1 oppose
✓ All Quality Gates Passed
Mechanistic 0.50 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.50 (12%) Impact 0.00 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.50 (6%) Data Avail. 0.50 (5%) Reproducible 0.50 (5%) KG Connect 0.12 (8%) 0.455 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite46%

🧪 Overview

Target DGAT1/DGAT2 inhibition or ATGL activation to restore metabolic homeostasis by addressing lipid metabolism dysfunction unique to APOE4 carriers

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["APOE4 Microglial Lipid Dyshomeostasis<br/>Excess Neutral Lipid Accumulation"]
    B["DGAT1 DGAT2 Overactivation<br/>Diacylglycerol to Triglyceride Conversion"]
    C["Lipid Droplet Overloading<br/>Organelle Function Impaired"]
    D["ATGL Lipase Activity Reduced<br/>Impaired Triglyceride Lipolysis"]
    E["DGAT1 DGAT2 Inhibitor Treatment<br/>A922500 DGAT1i or Prevents LD Formation"]
    F["ATGL Activator Treatment<br/>Restores Lipid Droplet Turnover"]
    G["Metabolic Homeostasis Restored<br/>Neutral Lipid Cleared"]
    H["Microglial Phagocytic Function Recovered<br/>Amyloid Debris Clearance"]
    A --> B
    B --> C
    D --> C
    E -.->|"reduces LD formation"| C
    F --> D
    E --> G
    F --> G
    G --> H
    style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

⚖️ Evidence

⚖️ Evidence Matrix5 supports0 contradicts
Supports
PubMed PMID 39201759
PubMedPMID:39201759medium
Supports
PubMed PMID 38340721
PubMedPMID:38340721medium
Supports
PubMed PMID 32559414
PubMedPMID:32559414medium
Supports
PubMed PMID 39154689
PubMedPMID:39154689medium
Supports
PubMed PMID 37648867
PubMedPMID:37648867medium
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — DGAT1

No curated PDB or AlphaFold mapping for DGAT1 yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for DGAT1 →

No DepMap CRISPR Chronos data found for DGAT1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0527
Events (7d)
0
Price History
▲5.7%

💾 Resource Usage

LLM Tokens
12,984
$0.0779
Total Cost
$0.0779

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF ATGL is genetically activated (ATGL overexpression or ATGL activator) in APOE4 knock-in mouse astrocytes THEN spatial memory and hippocampal CA1 neuronal metabolic function will improve, with reducImprovement in Morris water mazelatency to platform (≥25% reduction vs. APOE4 controls), 40% reduction in hippocampal C16:0 and C18:0 ceramide levels via LC-MS/— no observation —pending0.68
IF DGAT1 is pharmacologically inhibited (e.g., with DGAT1 inhibitor A922513 or DGAT1-targeted siRNA) in human iPSC-derived neurons from APOE4 carriers THEN intracellular lipid droplet accumulation wilSignificant reduction in lipid droplet number (≥40% decrease) and mean size (≥30% decrease) as quantified by Adipored staining and high-content imaging, with co— no observation —pending0.75
🔮 Falsifiable Predictions (2)
pendingconf 75%
IF DGAT1 is pharmacologically inhibited (e.g., with DGAT1 inhibitor A922513 or DGAT1-targeted siRNA) in human iPSC-derived neurons from APOE4 carriers THEN intracellular lipid droplet accumulation will decrease significantly compared to vehicle-treated controls within 72 hours using human iPSC-deriv
Predicted outcome: Significant reduction in lipid droplet number (≥40% decrease) and mean size (≥30% decrease) as quantified by Adipored staining and high-content imagin
Falsification: No significant change (p>0.05) or increase in lipid droplet accumulation despite verified DGAT1 inhibition, indicating lipid droplets in APOE4 neurons are not primarily DGAT1-dependent and the hypothe
pendingconf 68%
IF ATGL is genetically activated (ATGL overexpression or ATGL activator) in APOE4 knock-in mouse astrocytes THEN spatial memory and hippocampal CA1 neuronal metabolic function will improve, with reduced ceramides and increased mitochondrial respiration, within 4 weeks using APOE4/4 knock-in mouse mo
Predicted outcome: Improvement in Morris water mazelatency to platform (≥25% reduction vs. APOE4 controls), 40% reduction in hippocampal C16:0 and C18:0 ceramide levels
Falsification: No improvement in spatial memory performance, no reduction in toxic lipid species (ceramides/sphingomyelin), and no enhancement of mitochondrial respiration despite confirmed ATGL activation (ATGL pro
View on SciDEX ↗